Article Information
History
- May 3, 2023.
Article Versions
- You are currently viewing Version 1 of this article (May 3, 2023 - 11:54).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Danni A. Gadd1,2,
- Robert F. Hillary1,2,
- Zhana Kuncheva1,3,
- Tasos Mangelis1,3,
- Romi Admanit4,5,
- Jake Gagnon4,5,
- Tinchi Lin4,
- Kyle Ferber4,
- Heiko Runz4,
- Biogen Biobank Team,
- Riccardo E. Marioni*,1,2,†,
- Christopher N. Foley*,1,3 and
- Benjamin B. Sun4,6,*,†
- 1Optima Partners, Edinburgh, EH2 4HQ, UK
- 2Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, EH4 2XU, UK
- 3Bayes Centre, The University of Edinburgh, Edinburgh, EH8 9BT, UK
- 4Translational Sciences, Research and Development, Biogen Inc. Cambridge, MA, USA
- 5Global Analytics and Data Science, Research and Development, Biogen Inc., Cambridge, MA, USA
- 6Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, CB1 8RN, UK
- ↵*Correspondence: benjamin.sun{at}biogen.com and riccardo.marioni{at}ed.ac.uk.
↵* Equal contributions.
Posted May 03, 2023.
Blood protein levels predict leading incident diseases and mortality in UK Biobank
